Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

MedImmune venture capital arm leads financing of cancer drug developer G1

19:20 EDT 16 Oct 2013 | SCRIP

Chapel Hill, North Carolina-based G1 is studying a treatment for myelosuppression, a side effect of chemotherapy that limits production of blood cells and platelets. The company said it plans to file an investigational new drug application with the U...

Original Article: MedImmune venture capital arm leads financing of cancer drug developer G1

NEXT ARTICLE

More From BioPortfolio on "MedImmune venture capital arm leads financing of cancer drug developer G1"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story